McIlrath & Eck’s BioMarin Pharmaceuticals BMRN Stock Holding History

McIlrath & Eck’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-98	Closed	-$8.07K	–	984
2024 Q2	$8.07K	Hold	98	–	–	﹤0.01%	640
2024 Q1	$8.56K	Hold	98	–	–	﹤0.01%	629
2023 Q4	$9.45K	Hold	98	–	–	﹤0.01%	570
2023 Q3	$8.67K	Hold	98	–	–	﹤0.01%	571
2023 Q2	$8.49K	Hold	98	–	–	﹤0.01%	588
2023 Q1	$9.53K	Hold	98	–	–	﹤0.01%	558
2022 Q4	$10.1K	Buy	+98	New	+$9.2K	﹤0.01%	531

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

McIlrath & Eck's BMRN Position: Q3 2024 in Review

McIlrath & Eck sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 98 shares — an estimated $8.07K sold.

McIlrath & Eck first reported a position in BMRN in Q4 2022 and held it in 7 quarters. The position peaked at $10.1K in Q4 2022. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

McIlrath & Eck reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
McIlrath & Eck sold 98 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $8.07K.
McIlrath & Eck first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 7 quarters.
McIlrath & Eck's BioMarin Pharmaceuticals position peaked at $10.1K in Q4 2022.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on McIlrath & Eck's 13F filing for Q3 2024, filed 19 Nov 2024.